# Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function

> **NCT06623630** · PHASE1 · RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 16 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Ciltacabtagene Autoleucel
- **RADIATION:** Total body irradiation

## Key facts

- **NCT ID:** NCT06623630
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-04
- **Primary completion:** 2027-06-30
- **Final completion:** 2028-05-31
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2026-03-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06623630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06623630, "Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT06623630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*